GAINESVILLE, Fla., July 18, 2011 (GLOBE NEWSWIRE) -- Quick-Med Technologies, Inc. (OTCQB:QMDT), a life sciences company that is developing innovative technologies for the healthcare and consumer markets, announced today that the Patent Office of the Australian Government has issued another patent to protect the Company's intellectual property involving its NIMBUS technology.
The patent titled "Antimicrobial Cationic Polyelectrolyte Coating" covers the process for non-leachably bonding the NIMBUS active agent to wound dressings and various other substrates. It has been designated Australian Patent No. 2006283043.
"We are pleased that the patents underlying our NIMBUS intellectual property continue to issue globally, supporting our efforts to expand into promising international markets," said Dr. Jerry Olderman, Quick-Med's vice president of Research & Development. "NIMBUS is an important antimicrobial technology for medical devices because it doesn't leach or suffer depletion, doesn't initiate bacterial resistance, doesn't interfere with tissue healing and prevents odor generation," added Dr. Olderman.
NIMBUS technology provides a safe and effective structure for medical applications. This non-leachable configuration prohibits the depletion of the active polymer during use so that the product retains its initial high level of performance. Some antimicrobials initiate bacterial resistance when they are free to migrate and thus enter the bacteria or deplete to a level that is insufficient to inactivate or destroy the bacteria. Another advantage to using a bound active is that it doesn't interfere with wound healing as has been documented for silver containing dressings. The absorbent part of the dressing, in its action against microorganisms that are drawn into the dressing, prohibits a build-up of a bacterial population that can cause odor or would be free to re-enter the wound and contribute to renewal of an infectious environment.
About NIMBUS
Quick-Med's patented technology, NIMBUS, is a cutting-edge antimicrobial technology that has been custom designed for wound care and other medical applications. NIMBUS received De Novo clearance in 2009 from the U.S. Food and Drug Administration and has been commercialized in traditional wound care applications. It is the only non-leaching antimicrobial dressing which, by design, poses no risk of bacteria developing resistance. NIMBUS technology is protected by ten U.S. patents and patents pending and 24 foreign counterparts. Additional applications under development include advanced wound dressings, medical adhesives, and catheters.
About Quick-Med Technologies, Inc.
Quick-Med Technologies, Inc. is a life sciences company that is developing innovative technologies for the consumer and healthcare markets. The Company is developing advanced antimicrobial technologies for infection prevention and control. Its NIMBUS® technology is the first FDA-cleared, non-leaching antimicrobial available in a wound dressing. Its NimbuDerm™ technology is being developed as a persistent hand sanitizer and its new Stay Fresh® technology provides highly durable antimicrobial protection for apparel and other textile applications. For more information, see: www.quickmedtech.com/" target="_top" rel="nofollow">www.quickmedtech.com.
© 2011 Quick-Med Technologies, Inc. All rights reserved. NIMBUS® and Stay Fresh® are registered trademarks and NimbuDerm™ is a trademark of Quick-Med Technologies, Inc.
The Quick-Med Technologies, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=8260
Forward-looking statements (statements which are not historical facts) in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained in this release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may", "will", "to", "expect", "plan", "believe", "anticipate", "intend", "could", "would", "estimate", and/or "continue" or the negative or other variations thereof or comparable terminology are intended to identify forward-looking statements involve risks and uncertainties, including those risks that are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"), which may be accessed at the SEC's Edgar System at www.sec.gov.